Home » Stocks » PPD

PPD, Inc. (PPD)

Stock Price: $46.26 USD -0.01 (-0.02%)
Updated Apr 19, 2021 12:17 PM EDT - Market open
Market Cap 16.21B
Revenue (ttm) 4.68B
Net Income (ttm) 120.15M
Shares Out 350.43M
EPS (ttm) 0.35
PE Ratio 132.17
Forward PE 32.47
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $46.26
Previous Close $46.27
Change ($) -0.01
Change (%) -0.02%
Day's Open 46.17
Day's Range 46.15 - 46.49
Day's Volume 1,705,818
52-Week Range 21.46 - 46.49


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fair...

3 days ago - Business Wire

PPD, Inc. (PPD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

3 days ago - Zacks Investment Research

NEW YORK, April 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PPD, Inc. ("PPD" or the "Company") (NA...

3 days ago - PRNewsWire

PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable announced $78 million in new funding to fuel advances in the delivery of decentralized clinical trials and patient-centered research.

4 days ago - Business Wire


Other stocks mentioned: TMO
4 days ago - PRNewsWire

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces First Quarter 2021 Earnings Conference Call

1 week ago - Business Wire

Clinical trial leaders PPD and Charles River Labs test resistance and new buy points. The post Clinical Trial Leaders PPD And CRL Stock Test New Buy Points appeared first on Investor's Business Daily.

Other stocks mentioned: CRL
3 weeks ago - Investors Business Daily

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD and Clinical Ink have developed a systemic lupus erythematosus (SLE) assessment review process to simplify clinical trials for the chronic disease

3 weeks ago - Business Wire

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD has been recognized for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG)

1 month ago - Business Wire

PPD, Inc. (PPD) delivered earnings and revenue surprises of 11.43% and 6.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Reports Fourth Quarter and Full Year 2020 Results

1 month ago - Business Wire

PPD, Inc. (PPD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

3 months ago - Zacks Investment Research

The year has seen more than 370 companies go public, so finding the 10 best IPOs to invest in won't be easy. Here are the top contenders.

Other stocks mentioned: AZEK, FEAC, IPOB, IPOC, JWS, LSF, PSTH ...
5 months ago - InvestorPlace

Most experienced investors are well aware of the major indexes that compose the equity markets.

Other stocks mentioned: DKNG, HZNP, NET, CDAY
5 months ago - 24/7 Wall Street

PPD, Inc. (PPD) CEO David Simmons on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Investor sentiment remains strong for PPD, as shareholders have enjoyed almost 250% upside since the selloff in March. The stock has bounced away from support 7 times since then, in a narrow ascending c...

5 months ago - Seeking Alpha

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Other stocks mentioned: ASLN, LGND, LLY
6 months ago - Seeking Alpha

PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Pricing of Secondary Offering of Shares of Common Stock

7 months ago - Business Wire

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Secondary Offering of Shares of Common Stock.

7 months ago - Business Wire

LOS ANGELES, Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round.

7 months ago - PRNewsWire

PPD beats the Street by $84.5 million on revenues, but misses EPS by $0.15.

8 months ago - Seeking Alpha

PPD, Inc. (PPD) CEO David Simmons on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide drug deve...

8 months ago - Business Wire

The Renaissance IPO Index is up 37.7% year to date compared to -1.3% for the S&P 500. Here are seven new stocks to buy from this index.

Other stocks mentioned: LVGO, REYN, RPRX, WMG, ZI
9 months ago - InvestorPlace

PPD's (PPD) CEO David Simmons on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

PPD (NASDAQ: PPD) shares are trading higher on Friday, after Morgan Stanley maintained an Overweight rating and raised its price target from $26 to $30.

11 months ago - Benzinga

PPD - Fully Valued Drug Development Company

1 year ago - Seeking Alpha

PPD Inc. (NASDAQ: PPD) made an exciting entrance to the market Thursday.

1 year ago - 24/7 Wall Street

PPD Inc. shares soared 14% in their trading debut Thursday, after the drug research company's initial public offering priced at the high end of its $24 to $27 price range.

1 year ago - Market Watch

About PPD

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science... [Read more...]

Drug Manufacturers-Specialty & Generic
IPO Date
Feb 6, 2020
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, PPD, Inc.'s revenue was $4.68 billion, an increase of 16.14% compared to the previous year's $4.03 billion. Earnings were $153.69 million, an increase of 221.39%.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for PPD, Inc. stock is "Strong Buy." The 12-month stock price forecast is 43.75, which is a decrease of -5.43% from the latest price.

Price Target
(-5.43% downside)
Analyst Consensus: Strong Buy